NeuroOne Medical Technologies announced the first implant of its OneRF Ablation electrode by doctors at a top ranked hospital in the US, as ranked by the US News & World Best Hospital Report in its 2023-2024 publication. The OneRF Ablation system has FDA 510(k) clearance for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures. “We are excited to announce that yesterday, doctors implanted Evo sEEG-RF electrodes in a patient suffering from epilepsy. Once the monitoring identifies the areas of the brain that are causing seizures, the surgical team now has the option to use the same electrodes to perform an ablation utilizing NeuroOne’s RF generator. This capability provides the neurosurgeon an entirely new option for use in the appropriate patients and situation. Being first to market with this technology positions the Company as a market leader in offering multi-functional diagnostic and therapeutic thin-film electrode technology,” said Dave Rosa, CEO of NeuroOne. “As stated previously, we believe the technology has the potential to reduce hospital stays, number of surgeries, and adverse events, while offering significant clinical benefits including temperature control to enhance patient safety.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMTC:
- NeuroOne® Announces First Implant of OneRF™ Ablation Electrodes
- NeuroOne® CEO Dave Rosa Featured on Fox Business Network’s Varney & Co.
- NeuroOne® Initiates Limited Commercial Launch of OneRF™ Ablation System
- NeuroOne Medical initiates limited commercial launch of OneRF
- NeuroOne Medical Advances with Key Shareholder Decisions